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ABSTRACT
Drug resistance of cancer cells is recognized as the primary cause of failure of 
chemotherapeutic treatment in most human cancers. Growing evidences support the 
idea that deregulated cellular metabolism is linked to such resistance. Indeed, both 
components of the glycolytic and mitochondrial pathways are involved in altered 
metabolism linked to chemoresistance of several cancers. Here we investigated the 
drug-induced metabolic adaptations able to confer advantages to docetaxel resistant 
prostate cancer (PCa) cells. We found that docetaxel-resistant PC3 cells (PC3-DR) 
acquire a pro-invasive behavior undergoing epithelial-to-mesenchymal-transition 
(EMT) and a decrease of both intracellular ROS and cell growth. Metabolic analyses 
revealed that PC3-DR cells have a more efficient respiratory phenotype than sensitive 
cells, involving utilization of glucose, glutamine and lactate by the mitochondrial 
oxidative phosphorylation (OXPHOS). Consequently, targeting mitochondrial complex 
I by metformin administration, impairs proliferation and invasiveness of PC3-DR cells 
without effects on parental cells. Furthermore, stromal fibroblasts, which cause a 
“reverse Warburg” phenotype in PCa cells, reduce docetaxel toxicity in both sensitive 
and resistant PCa cells. However, re-expression of miR-205, a microRNA strongly 
down-regulated in EMT and associated to docetaxel resistance, is able to shift OXPHOS 
to a Warburg metabolism, thereby resulting in an elevated docetaxel toxicity in PCa 
cells. Taken together, these findings suggest that resistance to docetaxel induces a 
shift from Warburg to OXPHOS, mandatory for conferring a survival advantage to 
resistant cells, suggesting that impairing such metabolic reprogramming could be a 
successful therapeutic approach.
INTRODUCTION
Docetaxel (Taxotere®) is a standard chemotherapy 
for patients with castration resistant metastatic prostate 
cancer [1, 2]. However, docetaxel-based chemotherapy 
often encounters several undesirable adverse effects, and 
many patients display de novo or acquired resistance. To 
date, several factors have been associated with docetaxel 
resistance, including expression of different isoforms 
of β-tubulin [3], activation of drug efflux pumps [4], 
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PTEN loss [5], activation of survival pathways (i.e., 
PI3K/AKT and mTOR) [6] and recently also NOTCH2/
Hedgehog signaling pathways [7]. Recent findings both 
in vitro and from tumor samples support the presence 
of primary resistant cells harboring EMT/stem cell–like 
characteristics [8] suggesting a possible association 
between such aggressive features and chemotherapy 
failure. Interestingly, acquisition of metastatic 
characteristics is also associated with a specific 
metabolic reprogramming [9] and tumor metabolism has 
received increased attention over the last decade. Only 
recently the metabolic behavior has been implicated 
in tumor drug resistance [10-12]. Targeting tumor 
metabolism has been shown to represent an alternative 
way to overcome drug resistance and there are several 
approaches that have been demonstrated to be successful 
in pre-clinical models [13, 14]. However, the link 
between tumor metabolism and drug resistance is highly 
complex and depends on various conditions including 
oxygen and/or nutrient availability [15, 16] and can be 
influenced by the surrounding microenvironment [17]. 
Indeed, in tumor microenvironment, cancer-associated 
fibroblasts (CAFs) have been shown to promote 
aggressiveness of PCa cells in terms of EMT induction 
[18], OXPHOS metabolic shift [19, 20] and miRNAs 
deregulation [21]. In this study, we report a metabolic 
shift of docetaxel-resistant PCa cells from a glycolytic 
phenotype towards OXPHOS due to EMT engagement. 
We also demonstrate that CAFs are able to protect tumor 
cells from drug toxicity. Finally, in agreement with 
recent results highlighting the key role of microRNA 
in tumor progression [22], we focused our attention 
on miR-205 which is down-regulated in both CAF and 
docetaxel induced EMT [8, 21]. We demonstrated that 
overexpression of miR-205, associated with a reversion 
of OXPHOS metabolism, is crucial to sensitize PC3-DR 
to the drug.
RESULTS
PC3-DR cells acquire pro-invasive abilities 
and show decreased levels of ROS and 
pentose phosphate pathway flux
We established the PC3-DR cell line by treating 
sensitive PC3 cells with increasing doses of docetaxel up 
to a final concentration of 10 nM. PC3-DR cells achieve 
EMT as shown by cell morphology, EMT markers, 
increased cell invasion and secretion of interleukin-6 
(IL6), a marker of prostate cancer progression [23] 
(Supplementary Figure 1A-1E). Furthermore, PC3-DR 
cells show a decreased expression of several pro-apoptotic 
markers as well as an increased clonogenic potential as 
assessed by prostaspheres formation assay (Supplementary 
Figure 1E-1F).
Recently, it has been demonstrated that docetaxel 
treatment elicits a burst of ROS produced by NADPH 
oxidase [24]. Indeed, enhancement of ROS production 
is associated to many chemotherapeutic agents [24-27]. 
Therefore, the ability of cancer cells to handle oxidative 
stress is fundamental for the protection of cells against 
the cytotoxic effect of anti-cancer agents and hence for 
the development of chemoresistance. To gain insights on 
this aspect, we evaluated the ability of PC3-DR and PC3 
cells to manage ROS. As demonstrated in Figure 1A PC3-
DR cells have reduced ROS levels both in basal condition 
and following docetaxel treatment with respect to PC3 
sensitive cells. In agreement, treatment of sensitive PC3 
cells with the ROS scavenger N-acetylcysteine (NAC) 
decreases their sensitivity to docetaxel (Figure 1B). 
Recently, the activation of the pentose phosphate pathway 
(PPP) has been implicated in chemoresistance of cancer 
cells [28-30] through the production of NADPH required 
to fuel antioxidant systems. We evaluated the expression 
and activity of the key PPP rate limiting enzyme glucose-
6-phosphate dehydrogenase (G6PD) as well as PPP flux by 
radioactive assay in PC3-DR and in sensitive cells (Figure 
1C-1E). Surprisingly, we found a reduced expression and 
activity of G6PD (Figure 1C-1D) and a reduced PPP flux 
in the resistant cells (Figure 1E). Moreover, PC3-DR 
cells are insensitive to G6PD inhibitors, Molecular Clip 
and Tweezer [31] (Figure 1F), suggesting that docetaxel-
resistance does not depend on PPP activation in the model 
analyzed. Furthermore, NADPH levels are decreased in 
PC3-DR cells (Figure 1G). These results suggest that in the 
PC3 model PPP is not involved in counteracting oxidative 
stress induced by the drug. Interestingly, in agreement 
with a reduction of PPP flux, which is fundamental not 
only for NADPH synthesis but also for ribose 5 phosphate 
production to sustain nucleic acid synthesis and hence 
proliferation, we observed a decrease in cell growth of 
PC3-DR with respect to PC3 (Figure 1F).
Docetaxel resistant cells acquire a respiratory 
phenotype
To establish a potential correlation between 
docetaxel resistance and metabolic reprogramming, 
we analyzed proteins/enzymes involved in aerobic 
glycolysis and OXPHOS. To understand the metabolic 
adaptations of resistant cells following treatment with the 
drug and in order to reproduce circumstances occurring 
in vivo during treatment with the anti-cancer agent, we 
performed the experiments even in the presence of an 
acute treatment of docetaxel. As shown in Figure 2A 
PC3 cells have higher levels of Hexokinase II (HKII) and 
monocarboxylate transporter 4 (MCT4), that have been 
shown to be associated with Warburg metabolism, when 
compared to PC3-DR cells, independently of docetaxel 
treatment, suggesting that docetaxel resistance leads to 
an adaptation towards mitochondrial metabolism. Indeed, 
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Figure 1: PC3-DR cells have reduced levels of intracellular ROS, PPP flux and cell growth. A. Evaluation of intracellular 
ROS with H2DCF-DA fluorimetric analysis, normalized on protein content. The results are representative of four independent experiments. 
*p≤0.005 PC3-DR vs PC3 B. Evaluation of PC3 cells sensitivity to docetaxel in presence of NAC: PC3 cells were treated with 5 nM 
docetaxel for 24 h in the presence or not of 20 mM NAC. Cells viability was quantified by crystal violet assay. Bar graph represents the 
percentage of dead cells following treatments with respect to corresponding untreated cells. Results are representative of three experiments. 
*p<0.005 NAC vs untreated. C. Immunoblot analysis of G6PD expression levels in PC3 and PC3-DR cell lines. Actin immunoblot was 
used for normalization. D. G6PD activity assay in PC3 and PC3-DR cells. The results are representative of three experiments. *p≤0.05 
PC3-DR vs PC3. E. Analysis of PPP flux was obtained by subtracting the amount of CO2 developed from [6-
14C]-glucose from the CO2 
released from [1-14C]-glucose. The value is normalized on the protein content and expressed as fold change relative to PC3 cells. The results 
are representative of three experiments. *p≤0.005 PC3-DR vs PC3. F. Cell growth of PC3 and PC3-DR cells was evaluated by crystal violet 
staining in complete medium in the presence or not of 10 μM Molecular Clip or 3 μM Tweezer added fresh daily. *p≤0.005 PC3-DR vs 
PC3. G. Quantification of NADPH intracellular levels of PC3 and PC3-DR cells reported as fold change relative to PC3 cells. The results 
are representative of three experiments. *p≤0.005 PC3-DR vs PC3.
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Figure 2: Docetaxel resistant cells increase their oxidative metabolism. A. Immunoblot analysis of HKII and MCT4 in PC3 
and PC3-DR cells treated with or without 10 nM docetaxel in serum-free medium for 48 h. Actin immunoblot to ensure equal loading. B. 
Respiration of [14C]-glucose of PC3 and PC3-DR cells treated as in A) was evaluated by monitoring the [14C]-CO2 release and normalized 
on protein content. Results are shown as fold change relative to PC3 cells. The results are representative of four experiments. *p<0.05 
PC3-DR vs PC3. C. Respiration of [14C]-lactate of PC3 and PC3-DR cells treated as in A) was evaluated by monitoring the [14C]-CO2 
release and normalized on protein content. Results are shown as fold change relative to PC3 cells. The results are representative of three 
experiments. *p<0.01 PC3-DR vs PC3. D. qRT-PCR analysis of GLUT1 expression in PC3 and PC3-DR cells. Results are representative 
of three experiments. *p≤0.005 PC3-DR vs PC3. E. Evaluation of [14C]-glucose uptake was performed and normalized on protein content. 
Results are representative of three experiments. *p≤0.05 PC3-DR vs PC3. F. Cells were treated in the presence or absence of 40 μM DASA-
58 for 48 h in serum free medium. The amount of lactate released in the medium was quantified and plotted after protein normalization. 
Results are representative of three experiments. *p<0.01 vs PC3 without DASA-58; ≠p<0.01 vs PC3 without DASA-58. G. Respiration of 
[14C]-glucose of PC3 and PC3-DR cells treated as in F) was evaluated as [14C]-CO2 release and normalized on protein content. Results are 
representative of three experiments. * p<0.005 vs PC3-DR without DASA-58.
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analysis of radiolabeled carbon sources fluxes shows that 
docetaxel resistant cells exhibit an increased glucose and 
lactate oxidation to CO2 through mitochondrial respiration 
(Figure 2B-2C) accompanied by a decrease in GLUT1 
expression and glucose uptake (Figure 2D-2E). To sustain 
the key role of OXPHOS in supporting chemoresistance, 
we demonstrated that in hypoxic conditions, where both 
HKII and MCT4 expression increases, thus restoring 
Warburg metabolism, PC3-DR cells become more 
sensitive to docetaxel (Supplementary Figure 2). In 
agreement, another prostate cell line, namely the DU-145, 
exhibits a similar respiratory phenotype after acquisition 
of docetaxel resistance and mesenchymal phenotype as 
shown by increased levels of glucose and lactate oxidation 
and a decrease in glucose uptake; in keeping DU-145-
DR cells show an increase in c-Myc expression (a key 
regulator of mitochondrial respiration) and a decrease 
in HKII levels (Supplementary Figure 3A-3C). Taken 
together, these data support the existence of a shift towards 
the oxidative mitochondrial metabolism to sustain the 
acquisition of the docetaxel resistance phenotype.
To deep analyze the fate of pyruvate produced in 
PC3-DR and PC3 cells, we administrated DASA-58, 
a molecule that induces pyruvate kinase M2 (PKM2) 
tetramerization (hence activation) and thus pyruvate 
production [32]. Upon DASA-58 administration we 
demonstrated that resistant and sensitive cells show 
differential behavior: PC3 cells, through the conversion 
of pyruvate into lactate, show a marked increase of lactate 
levels in the medium, while PC3-DR cells do not change 
their lactate production (Figure 2F), but increase glucose-
fueled oxidation through OXPHOS (Figure 2G). To better 
clarify the engagement of mitochondrial respiration in 
docetaxel resistant cells, we used metformin, an inhibitor 
of the mitochondrial complex I activity, to test its effect 
on both cell growth and invasion of these two cell types. 
As shown in Figure 3A-3D in docetaxel resistant cells 
metformin selectively inhibits growth, invasiveness, 
MMPs secretion and Zeb1 expression. These effects 
are correlated with the disruption of the mitochondrial 
respiratory function, suggesting that PC3-DR cells 
are likely dependent on it. Indeed, metformin causes 
a change in the metabolic behaviour of cancer cells as 
shown by the upregulation of HKII, MCT4 and GLUT1 
expression thus shifting the metabolism towards a clear 
glycolytic one and consequently impairing the features of 
mitochondrial dependent cells (Figure 3E-3F). To further 
support the involvement of mitochondrial respiration 
in docetaxel resistant cells we used other OXPHOS 
inhibitors (rotenone, antimycin and oligomicin) to assess 
the sensitivity to docetaxel. As shown in Supplementary 
Figure 4, OXPHOS inhibitors affect more efficiently 
PC3-DR survival, confirming a strict connection between 
resistance and mitochondrial respiration.
It has been shown that cancer cells are also 
dependent on glutamine to maintain the TCA cycle 
[33]. Moreover, it has been demonstrated that c-Myc is 
implicated in glutamine metabolism and contributes to 
metabolic reprogramming essential for cancer cells to 
adapt to the tumour microenvironment, being involved 
also in ribosomal and mitochondrial biogenesis, glucose 
metabolism as well as lipid synthesis [34]. Interestingly, 
we found a strong up-regulation of c-Myc in PC3-
DR cells (Figure 4A). To test the dependence of PC3-
DR cells on glutamine, we investigated cell growth in 
the presence of a single carbon source in the medium. 
As shown in Figure 4B, PC3-DR cells exhibit higher 
glutamine-fuelled growth, compared to parental cells. 
Furthermore, inhibition of glutaminase, the key enzyme 
for mitochondrial glutamine utilization, strongly affects 
the invasive abilities of resistant cells (Figure 4C). In 
line with these data, PC3-DR cells exhibit an increased 
glutamine uptake and oxidation through OXPHOS 
(Figure 4D-4E). These data are consistent with both an 
increased mitochondrial metabolism and the acquisition 
of glutamine dependence in docetaxel resistant cells. 
Accordingly, c-Myc silencing is able to sensitize PC3-DR 
cells to docetaxel as shown in Figure 4F-4G, suggesting a 
strong dependence of PC3-DR cells on c-Myc axis.
Metabolic reprogramming towards OXPHOS and 
the acquisition of mesenchymal traits of the PC3-DR cells 
was further supported by data mining of publicly available 
gene expression profile of PCa cells that display resistance 
to docetaxel [35]. In such a model, a class of genes 
associated with OXPHOS metabolism are upregulated in 
the docetaxel resistant cell line: pyruvate dehydrogenase 
(E1) α subunit gene (PDHA1), monocarboxylate 
transporter 1 (MCT1), Dihydrolipoamide dehydrogenase 
(DLD), MYC, Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PPARGC1A); whereas, 
genes found to be associated with aerobic glycolysis are 
down-regulated: MCT4, HK2, TP53 Induced Glycolysis 
Regulatory Phosphatase (TIGAR), when compared to 
wild type PC3 cells. Additionally, this in silico analysis 
confirmed the acquisition of mesenchymal traits of PC3 
cells resistant to docetaxel. Indeed, vimentin, Snai2, Zeb1 
and Twist2 were upregulated and Cdh1 down-regulated 
in resistant cells when compared to wild type PC3. 
Noteworthy, miR-205, an established regulator of EMT 
engagement in PC3 cells [8, 21], was found accordingly 
down-regulated (Figure 5).
Cancer associated fibroblasts induce docetaxel 
resistance in PCa cells
In the context of prostate cancer progression we 
demonstrated that OXPHOS induction is a common 
feature of both CAF induced metabolic reprogramming 
and miR-205 down-regulation [19-21] as well as drug 
resistance. Thus, we investigated the role of CAF and 
miR-205 modulation on chemosensitivity of PC3 cells. To 
this end we first tested whether stromal fibroblasts could 
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Figure 3: Metformin impairs growth and invasion of PC3-DR cells. A. Analysis of PC3 and PC3-DR cells growth in 10 % FBS 
medium for 48 h in presence of 10 nM docetaxel and/or 5 mM metformin by crystal violet assay. Absorbance at T0 of untreated PC3 and 
untreated PC3-DR cells was used as control. The results are representative of three experiments. *p<0.005 Metformin treated vs untreated. 
B. Boyden invasion assay of PC3 and PC3-DR cells treated or not with 5 mM metformin. Bar graph represents the mean of invaded cells in 
six-fields/sample. Number of invaded cells was expressed as fold change relative to PC3 cells without metformin. §p<0.05 vs PC3 without 
metformin; ≠p<0.05 vs PC3-DR without metformin. C. MMPs activity in PC3 and PC3-DR cells, treated or not with 5 mM metformin, 
was evaluated by gelatine zymography. Clear bands represent areas of gelatinase activity. The results shown are representative of four 
independent experiments with comparable results. Medium from HT1080 cell was used as positive control. D. qRT-PCR analysis of Zeb1 
expression was analyzed. Results are representative of three experiments. ≠p<0.005 metformin treated vs untreated; *p<0.005 PC3-DR 
vs PC3. E. Immunoblot analysis of HKII and MCT4 of total cell lysates from PC3 and PC3-DR cells treated or not with 5 mM metformin 
and/or 10 nM docetaxel for 48 h in serum-free medium. Actin immunoblot was used for normalization. F. qRT-PCR analysis of GLUT1 
expression levels was analyzed. Results are representative of three experiments. *p<0.005 metformin treated vs untreated PC3; ≠p<0.005 
metformin treated vs PC3-DR.
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Figure 4: PC3-DR cells acquire glutamine addiction. A. Immunoblot analysis of c-Myc in PC3 and PC3-DR cells treated with or 
without 10 nM docetaxel for 48 h in serum-free medium. Actin immunoblot was used for normalization. B. Evaluation of PC3 and PC3-DR 
cells growth in medium containing either glucose (25 mM), pyruvate (1 mM) or glutamine (2 mM) was analyzed by crystal violet assay 
for 48 h. Results are representative of three experiments. *p<0.005 PC3-DR vs PC3; ≠p<0.05 PC3-DR vs PC3. C. Boyden invasion assay 
of PC3 and PC3-DR cells treated or not with 10 μM glutaminase inhibitor (compound 968). Bar graph represents the mean of invaded 
cells in six field for sample. Number of invaded cells was expressed as fold change respect to PC3 cells without metformin. Results are 
representative of three independent experiments. *p<0.005 treated vs untreated. D. Evaluation of [14C]-glutamine uptake of PC3 and PC3-
DR cells treated or not with 10 nM docetaxel for 48 h and normalized on protein content. Results are representative of three experiments. 
*p<0.005 vs PC3. E. Respiration of [14C]-glutamine in PC3 and PC3-DR cells treated as in D) was evaluated as [14C]-CO2 release and 
normalized on total protein content. Results are shown as fold change relative to PC3 cells. Results are representative of four experiments. 
*p<0.005 vs PC3. F. Immunoblot analysis of c-Myc in PC3-DR cells silenced with control siRNA or c-Myc siRNA after 48 h from 
transfection. Actin immunoblot was used for normalization. G. PC3-DR cells were transfected with control siRNA or c-Myc siRNA. After 
24 h from transfection cells were treated or not with 20 nM docetaxel for 48 h. Cells viability was then quantified by crystal violet assay. 
Bar graph represents the percentage of dead cells following docetaxel treatment with respect to untreated cells. Results are representative 
of three experiments. *p<0.005 c-myc sil PC3-DR vs control PC3-DR.
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affect PC3 cells chemosensitivity to docetaxel. Indeed, 
stromal cells are effective in supporting the survival of 
PC3-DR cells (10 nM resistant) when treated with an 
increased concentration of the drug (20 nM) (Figure 6A). 
Moreover, we observed that CAFs promote also the onset 
of PC3 cells resistance to docetaxel treatment as shown by 
co-culturing sensitive PC3 cells with CAFs in the presence 
of docetaxel (Figure 6B). Therefore, we suggest that the 
stromal compartment is able to counteract docetaxel 
toxicity through the establishment of an oxidative 
metabolic phenotype.
In our previous reports we demonstrated that miR-
205 is one of the most down-regulated miRNA in PCa 
cells undergoing EMT and OXPHOS induction upon CAF 
contact [20, 21]. In our model we observed that OXPHOS 
engagement of PC3-DR cells is correlated to a down-
regulation of miR-205 expression with respect to PC3 
cells, too (Figure 7A). Thus, we evaluated whether miR-
205 re-expression could change the metabolic behavior of 
PCa cells. Indeed, ectopic miR-205 expression results in 
increased HKII expression and GLUT1 mRNA levels, as 
well as an increase in lactate production (Supplementary 
Figure 5 and Figure 7B-7D), suggesting an elevated 
glycolytic flux. Furthermore, an increase of glucose uptake 
and a decrease of mitochondrial glucose oxidation are 
observed following miR-205 overexpression in PC3-DR 
cells (Figure 7E-7F).
Finally, we evaluated whether this shift towards 
the glycolysis could be associated with increased 
chemosensitivity of PC3-DR cells. As expected, ectopic 
Figure 5: Gene expression analysis of PC3 and docetaxel-resistant derivatives. GDS3973 data [35] were retrieved as described 
in Material and Methods and transcripts of relevant genes involved in central carbon metabolism and EMT process were monitored. Box 
plots represent min, max and median value. Relative mRNA changes (fold increase PC3-DR vs PC3) are reported. **p<0.01 vs PC3, 
***p<0.001 vs PC3.
Figure 6: CAFs reduce sensitivity to docetaxel-induced apoptosis. A. PC3-DR cells were cultured alone or co-cultured with 
CAFs (ratio CAFs:PC3 2:1) for 48 h in complete medium prior to 20 nM docetaxel treatment for additional 72 h. PCa cells were then 
isolated using immunomagnetic beads targeting fibroblasts and stained with Annexin V and Propidium Iodide and apoptosis was evaluated 
by flow cytometer. §p<0.01vs PC3-DR cells alone treated with docetaxel. B. Analysis of docetaxel-induced apoptosis with Annexin V/
Propidium Iodide cytofluorimetric staining. PC3 cells were cultured alone or co-cultured with CAFs (proportion CAFs:PC3 2:1) for 48 
h prior to 10 nM docetaxel treatment for further 72 h. PC3 cells were then negatively isolated using immunomagnetic beads targeting 
fibroblasts and stained with Annexin V and Propidium Iodide and apoptosis was evaluated by flow cytometry. *p<0.01 vs PC3 cells alone 
treated with docetaxel.
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Figure 7: Re-expression of miR-205 in PC3-DR cells induces a metabolic shift and increase docetaxel sensitivity. A. qRT-
PCR analysis of miR-205 expression in PC3 and PC3-DR cells. Results are representative of three experiments. *p<0.005 PC3-DR vs PC3. 
B. Immunoblot analysis of HKII of PC3 and PC3-DR transfected with miR-205 or miR-neg for 48 h and then treated with or without 10 nM 
docetaxel for 48 h in serum-free medium. Actin immunoblot was used for normalization. C. qRT-PCR analysis of GLUT1 expression was 
evaluated in cells as in B). Results are representative of three experiments. *p<0.005 miR-205 transfected vs miR-neg transfected; ≠p<0.01 
miR-205 transfected vs miR-neg transfected. D. Cell were treated as in B) and lactate in media was evaluated. *p<0.01 miR-205 transfected 
vs miR-neg transfected; ≠p<0.005 miR-205 transfected vs miR-neg transfected. E. Evaluation of [14C]-glucose uptake was performed in 
PC3 and PC3-DR cells treated as in B) and normalized on protein content. Results are representative of three experiments. *p<0.01 miR-
205 transfected vs miR-neg transfected; §p<0.001 miR-205 transfected vs miR-neg transfected. F. Respiration of [14C]-glucose of PC3 and 
PC3-DR cells treated as in B) was evaluated as [14C]-CO2 release and normalized on protein content. Results are representative of three 
experiments. *p<0.005 miR-205 transfected vs miR-neg transfected; §p<0.05 miR-205 transfected vs miR-neg transfected. G. PC3-DR 
cells were transfected with miR-205 or miR-neg for 24 h and then treated or not with 20 nM docetaxel for 48 h. Cells were then quantified by 
crystal violet assay. Bar graph represents the percentage of dead cells following docetaxel treatment with respect to untreated cells. Results 
are representative of four experiments. *p<0.005 miR-205 transfected PC3-DR vs miR-neg transfected PC3-DR.
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overexpression of miR-205 in PC3-DR cells sensitizes 
resistant cells to docetaxel treatment (Figure 7G). 
Similar results were obtained also in DU145-DR cells 
(Supplementary Figure 6).
DISCUSSION
It is well known that cancer cells are able to rewire 
their metabolism and energy production networks to 
support and enable rapid proliferation, for survival in 
severe conditions and for increased invasion, metastasis 
and chemoresistance [12, 36-38]. Our results highlight that 
docetaxel resistant prostate cancer cells plastically shift 
their metabolism from aerobic glycolysis to OXPHOS and 
that metabolic adaptation is related to the commitment 
of EMT, increased invasion and achievement of stem-
like traits. Furthermore, the acquisition of docetaxel 
resistance is associated with down-regulation of miR-205, 
whose reduced expression has been previously linked to 
a respiratory phenotype [20]. Moreover, our data suggest 
a possible modulation of miR-205 to sensitize cells to 
docetaxel administration.
Some papers highlighted that an increased 
glycolytic flux accompanied by activation of the PPP is 
implicated in chemoresistance of cancer cells [29, 32]. 
The NADPH coenzyme, produced during oxidative phase 
of PPP, is crucial to provide the reducing equivalents for 
redox reaction involved in protecting against ROS. Our 
data demonstrate that docetaxel-resistant PCa cells do not 
rely on PPP. At the same time an important physiological 
adaptation consists in a decrease of their ROS content. 
Indeed, resistant cells show low proliferation rate (Figure 
1F) and do not need to fuel anabolic pathways from PPP 
or glycolysis, so allowing OXPHOS addiction.
In this study we analyzed the metabolic adaptation 
of PCa cells due to their achievement of docetaxel 
resistance. We observed that PC3-DR cells shift from 
Warburg metabolism toward mitochondrial respiration, 
in order to acquire a metabolic advantage. This metabolic 
conversion is confirmed by both down-regulation of 
glycolytic markers (HKII and MCT4) and increased 
utilization of radiolabeled carbon source (glucose, 
lactate and glutamine) through oxidative mitochondrial 
respiration (Figures 2-4). Although cancer cells are often 
characterized by intense glycolysis, even in the presence 
of oxygen (Warburg effect), mounting evidence underlines 
the role of OXPHOS in cancer progression and metastasis. 
Actually, Viale et al., demonstrated that pancreatic tumour 
cells, surviving oncogene ablation and responsible for 
tumour relapse, rely on OXPHOS for survival [39]. Sun 
et al., showed the existence of a shift towards OXPHOS 
during EMT of drug resistant lung cancer cells [40]. 
Acquisition of chemoresistance to temozolomide in 
glioma is associated with efficient mitochondrial coupling 
and reduced ROS production [41]. More recently, the 
group of Kalluri showed that the Peroxisome proliferator-
activated receptor gamma coactivator 1-α (PGC-1α)-
mediated mitochondrial biogenesis and respiration in 
cancer cells is functionally relevant for tumour cells 
motility and metastatic dissemination [42]. Finally, in 
support of our findings, Lamb et al., proposed the use of 
antibiotics to target mitochondria of cancer stem cells for 
multiple tumour types [43].
Few data are known about prostate cancer 
metabolism but a recent study has shown that patients 
bearing mitochondrial malate dehydrogenase 2 (MDH2) 
overexpression have shorter relapse free survival after 
neoadjuvant chemotherapy [44]. Moreover, inhibition 
of MDH2 in PCa cell lines increase the chemotherapy 
efficacy [44]. Our data suggest the involvement of 
mitochondrial respiration in the acquisition of docetaxel 
resistance as confirmed by ability of metformin to 
selectively inhibit both proliferation and invasion of 
resistant cells (Figure 3). Actually the inhibitory effect 
of metformin is not completely able to re-sensitize 
resistant cells to docetaxel, probably due to the existence 
of other compensatory mechanisms. Notably, we 
showed docetaxel-resistant cells as great exploiters of 
glutamine. Accordingly, overexpression of c-Myc was 
associated with sensitization to the anti-proliferative 
effects of metformin, consistent with c-Myc involvement 
in “glutamine addiction” [45]. Metformin acts directly 
on the mitochondria to inhibit OXPHOS and reduce 
mitochondrial ATP production, thus forcing tumor 
cells to compensate by increasing glycolysis rate [46]. 
Docetaxel-resistant cells - that rely heavily on OXPHOS 
for energy production – show a glycolytic switch and, 
consequently, an energy crisis associated to the loss of 
malignant phenotype, upon metformin treatment. For 
this reason, metformin could be used to exploit this 
metabolic weakness in resistant cells, circumventing 
treatment resistance and enhancing treatment efficacy. 
Accordingly, prostate cancer stem cells have been 
shown to be a good target for metformin treatment [46]. 
In addition, the PKM2-activator DASA-58, a well-
known molecule that allows the escape from Warburg 
metabolism [32], is able to potentiate glucose oxidation 
to CO2 only in resistant cells, whereas sensitive cells are 
induced to produce lactate (Figure 2F-2G). In line, gene 
expression analysis retrieved from publicly available 
microarray analysis of PC3 cells that are resistant to 
docetaxel revealed an upregulation of PDHA1 mRNA 
expression, suggesting the increase of pyruvate oxidation 
in TCA cycle and the upregulation of PPARGC1A crucial 
for enhanced OXPHOS, mitochondrial biogenesis 
and oxygen consumption rate (Figure 5). Overall, it 
is possible that the recovery of OXPHOS subtracts 
intermediates from anabolic processes and from PPP, to 
drive ATP production. Thus, ATP may be used to enhance 
the activity of multi drug resistant (MDR) transporter in 
order to extrude the drug.
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The crucial role of OXPHOS in metabolic 
reprogramming induced by CAF and miR-205 down-
regulation [19-21] as well as in the induction of docetaxel 
resistance, suggested us to investigate the role of both 
stroma and miR-205 modulation in chemoresistance. 
Indeed, we demonstrated that CAFs promote the onset of 
PCa cells resistance to docetaxel as well as the survival 
of resistant tumor cells when exposed to increased 
concentration of the drug (Figure 6), thus playing a 
crucial role in protecting tumor cells against docetaxel 
toxicity. Accordingly, some papers show that CAFs 
provide an important niche for the development of drug 
resistant cancer cells, in part through paracrine signaling 
interactions with cancer cells and cancer stem cells [47, 
48].
Moreover, aberrant expression of several miRNAs 
leads to the development of resistant prostate cells [22]. 
Among the others, down-regulation of miR-205 has been 
already linked to poor therapeutic outcome of prostate 
cancer patients [49]. Down-modulation of miR-205 results 
in upregulation of the anti-apoptotic protein Bcl2 [50] as 
well as down-regulation of E-cadherin, increase of Zeb 1 
and Zeb2 [23, 51]. Consistently Puhr et al., demonstrated 
that miR-205 down-regulation is responsible for the 
acquisition of EMT in docetaxel resistant PCa cells [8] as 
well as with the acquisition of respiratory phenotype upon 
CAF contact [8, 20]. The close correlation between miR-
205 and OXPHOS suggested us the possibility to modulate 
this miRNA to hinder chemoresistance. Indeed, we have 
shown that the ectopic expression of miR-205 reverts the 
OXPHOS addiction of PC3-DR, closely connected with 
the detoxifying ability of these cells (Figure 7). Finally, we 
observed that PCa cells metabolic reprogramming elicited 
by drug resistance is based on OXPHOS as mandatory 
feature of cancer malignancy. Indeed, disruption of 
this metabolic state by drug poisoning OXPHOS or 
by overexpressing miR-205 make resistant cells more 
sensitive to the docetaxel, implicating that drug resistance 
could be circumvented. The evidences highlighted in this 
manuscript could be relevant in a future clinical context, 
providing the rationale for using OXPHOS inhibitors to 
target metabolic reprogramming and counteract resistance 
to docetaxel.
Overall, our findings suggest that the combination 
of chemotherapy and OXPHOS inhibition may limit 
docetaxel-associated drug resistance and progression 
towards metastatic disease.
MATERIALS AND METHODS
Materials
Unless specified, all reagents were obtained from 
Sigma and all the antibodies were from Santa Cruz 
Biotechnology, except for anti-IL-6 (AbCam). Matrigel 
Matrix was purchase from BD Biosciences. [U-14C] 
lactate, [U-14C] glucose and [U-14C] glutamine were 
from Perkin Elmer. All kits used to perform miRNA 
extraction and quantitative reverse transcriptase PCR 
were bought from Qiagen. c-Myc siRNA (sc-29226) 
and Control siRNA-A (sc-37007) were from Santa Cruz. 
Lipofectamine 2000 and Lipofectamine RNAiMAX 
Reagent were from Invitrogen. Metformin was obtained 
from Sigma. Glutaminase Inhibitor (compound 968) was 
purchased by Calbiochem. Molecular Clip and Tweezer 
were provided by Prof. T. Schrader (University of 
Duisburg-Essen, Germany); DASA-58 was synthesized 
by Prof. C. Nativi and B. Richichi, Department of 
Biochemistry, University of Florence.
Cell cultures
PC3 were purchased from the European Collection 
of Cell Cultures (ECACC). DU145 and DU145 docetaxel-
resistant cells (12.5 nmol/L) were a kind gift of Dr. M. 
Puhr (Medical University of Innsbruck, Austria). PC3 
cells were cultured in DMEM containing 10 % Fetal 
Bovine Serum (FBS). DU145 were cultured in RPMI-
1640 medium supplemented with 10 % Fetal Calf Serum 
(FCS). CAFs were isolated from surgical explants after 
patients’ informed consent as previously described [19], 
in accordance with the Ethics Committee of the Azienda 
Ospedaliera Universitaria Careggi, Florence. PC3 
sensitive cells were converted to PC3-DR by exposing 
them to an initial dose of 1 nmol/L docetaxel and culturing 
surviving cells during 1 year with increasing doses (2.5, 5, 
7.5 nmol/L) until the final concentration of 10 nmol/L, as 
previously described [35].
Co-cultures separation
PC3 cells and fibroblasts were plated in a 1:2 ratio 
for co-culturing. Cells were then detached with Accutase 
(Life Technologies) and separated with MACS Column 
Technology (Miltenyi Biotec) by using anti-Fibroblast 
MicroBeads (Miltenyi Biotec) for positive selection of 
fibroblasts.
Transfection
miR-205 precursor (hsa-miR-205-5p) and negative 
control were purchased as Pre-miR™ (Ambion). Cells 
were transfected using Lipofectamine-2000 following 
manufacturer’s instructions. c-Myc siRNA and Control 
siRNA-A were transfected using Lipofectamine 
RNAiMAX Reagent according to manufacturer’s 
instructions.
Western blot analysis
Cells were lysed in RIPA buffer and 20-50 μg of 
total proteins were loaded on precast SDS-PAGE gels 
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(BioRad). Western blot analysis was performed as 
previously described [18].
Assay of intracellular reactive oxygen species 
(ROS)
To evaluate intracellular ROS content, cells were 
treated for 5 min with 5 μg/ml H2DCF-DA (Sigma). 
After PBS washing, cells were lysed in RIPA buffer and 
analyzed immediately by fluorimetric analysis at 510 nm. 
Data have been normalized to total protein content.
Prostasphere formation
Cells were detached using Accutase (Sigma). For 
prostasphere formation, single cells were plated at 150 
cells/cm2 on low attachment 100-mm plate (Corning) in 
DMEM/F12 (Invitrogen) supplemented with B27 and N2 
(Invitrogen), 5 μg/mL insulin, 20 ng/mL basic fibroblast 
growth factor, and 20 ng/mL epidermal growth factor. 
Cells were grown under these conditions for 21 days and 
then prostaspheres were photographed as representative 
images.
Gelatin zymography
Serum-free medium from confluent monolayer of 
cells was collected and 20 μL were added to the sample 
buffer (SDS 0.4%, 2 % glycerol, 10 mmol/L Tris-HCl, 
pH 6.8, 0.001 % bromphenol blue). The sample was 
run on a 10 % SDS gel containing 0.1 % gelatin. After 
electrophoresis, the gel was washed twice with 2.5 % 
Triton X-100 and once with reaction buffer (50 mmol/L 
Tris-HCl (pH 7.5), 200 mmol/L NaCl, 5 mmol/L CaCl2). 
The gel was incubated overnight at 37°C with freshly 
added reaction buffer and stained with Laemli Comassie 
blue solution. Areas of gelatinase activity appear as clear 
bands against a dark background.
In vitro boyden invasion assay
Invasion assay was performed with 8 × 104 cells on 
8-μm-pore Transwells (Corning) coated with 50 μg/cm2 
of reconstituted Matrigel for 16 h, as described in [52]. 
Chemotaxis was evaluated by counting the cells migrated 
to the lower surface of the filters (six randomly chosen 
fields).
Cell treatments and cell growth assay
After plating cells, medium was changed with fresh 
medium containing either glucose, sodium pyruvate or 
glutamine (25, 1 or 2 mmol/L) or both in the absence or 
presence of metformin (5 mmol/L), compound 968 (10 
μmol/L), N-acetylcysteine (20 mmol/L), antimycin (1 
μmol/L), oligomycin (500 nmol/L) or rotenone (5μmol/L) 
for another 12, 48, or 72 h, depending on the experiment. 
Cell growth was determined by crystal violet staining. 
At indicated times, cells were washed twice with PBS 
and crystal violet solution (0.5 % in 20 % methanol) was 
added and incubated for 15 min. The remaining crystals 
were dissolved with 0.1 M sodium citrate (pH 4.2). 
Viability was determined by absorbance at 595 nm using 
a spectrophotometric reader.
Real time RT-PCR
Total RNA from PC3 cells was extracted using 
RNeasy (Qiagen) according to the manufacturer’s 
instructions. Strands of cDNA were synthesized 
using QuantiTect Reverse Transcription Kit 
(Qiagen) using 1 μg of total RNA. mRNA 
expression was performed using QuantiFast SYBR 
Green (Qiagen). The primers for ZEB1 were: 
5’-AGCAGTGAAAGAGAAGGGAATGC-3’(forward), 
5’ GGTCCTCTTCAGGTGCCTCAG-3’ (reverse); for 
ZEB2: 5’-GGCATATGGTGACGCACAA-3’ (forward), 
5’-TTGAACTTGCGGTTACCTGC-3’ (reverse); 
for GLUT1 5’-CGGGCCAAGAGTGTGCTAAA-3’ 
(forward), 5’-TGACGATACCGGAGCCAATG-3’ 
(reverse). Data were normalized on β-2 microglobulin. 
Results are shown as the mean of three different 
experiments ±SD. For quantification of miR-205 
expression levels, total RNA, including small RNAs, was 
purified using miRNeasy kit. The reverse transcription 
reaction of 1 μg of total RNA was carried on using 
miScript II RT kit and the quantification of miR-205 
expression level was assessed by Real Time PCR using 
miScript SYBR Green PCR kit and miScript Primer 
Assay-HsmiR-205. SNORD61 was used as normalizer 
(miScript Primer Assay-HsSNORD61, Qiagen). All the 
amplifications were run on 7500 Fast Real-Time PCR 
System. Data were reported as relative quantity with 
respect to the calibrator sample using the 2-ΔΔCt method.
Lactate assay
Lactate levels were determined using a lactate 
assay kit (BioVision) according to the manufacturer's 
instructions. All data were normalized on cell protein 
content.
Radioactive metabolic assays
A) Radioactive glucose, lactate or glutamine 
uptake was evaluated by treating cells with a buffered 
solution (140 mmol/L NaCl, 20 mmol/L Hepes/Na, 2.5 
mmol/L MgSO4, 1 mmol/L CaCl2, and 5 mmol/L KCl, 
pH 7.4) containing 0.5 μCi/mL [U-14C] glucose, [U-14C] 
lactate [U-14C] glutamine for 15 min at 37°C. Cells were 
subsequently washed with cold PBS and lysed with 0.1 
mol/L NaOH. Incorporated radioactive was assayed by 
liquid scintillation counting and normalized on protein 
content. B) For the detection of CO2 released from 
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radioactive substrates, cells were incubated with 0.2 μCi/
mL or 0.5μ Ci/mL [U-14C] lactate or [U-14C]-glucose and 
glutamine for 15 min into 35 mm-dish. Each dish had a 
taped piece of Whatman paper facing the inside of the 
dish wetted with 100 μL of phenyl-ethylamine-methanol 
(1:1) to trap the CO2. Then 200 μL of 4M H2SO4 was 
added to cells. Finally, Whatman paper was removed 
and transferred to scintillation vials for counting. C) 
PPP activity was evaluated by using [1-14C]-glucose and 
[6-14C]-glucose. 14CO2 developed from [1-
14C]-glucose 
oxidation originates by the PPP or by the TCA cycle, 
whereas 14CO2 released from [6-
14C]-glucose originates 
only by TCA cycle. 2 μCi [1-14C]-glucose or 2 μCi [6-14C]-
glucose were added for 1 h to cells, in two different plates 
of same sample. Then, CO2 released was measured as 
above. The extent of PPP metabolic flux was obtained by 
subtracting the amount of CO2 developed from [6-
14C]-
glucose from the CO2 released from [1-
14C]-glucose.
G6PD activity assay
Cell lysis was performed at 4°C in 50 mM Tris/
Hcl pH 7.4, containing protease inhibitors. After 30 
min of incubation on ice, lysates were sonicated and 
centrifuged at 12,000 g in a microcentrifuge at 4°C for 30 
min. Supernatants were quantified with respect to protein 
content by Bradford assay (Biorad). G6PD activity was 
assayed following NADPH absorbance at 340 nm over 20 
min (ε = 6.22 mM−1 cm−1).
Evaluation of NADPH level
NADPH levels were determined using a NADP/
NADPH Quantitation Colorimetric Kit (BioVision) 
according to the manufacturer's instructions. All data were 
normalized on protein content.
Evaluation of apoptotic cell death
Cells were detached, washed with PBS and 
resuspended in 100 μl of buffer solution (Thermo 
Fischer Scientific) containing 1μl of Annexin V and 
1μl of Propidium Iodide. After 15 min incubation at 
room temperature, cell staining was evaluated by flow 
cytometry, gating for positivity to Annexin V and/or 
Propidium Iodide.
Gene expression analysis of publicly available 
datasets
GDS3973 data [35] were retrieved from GEO 
profiles. The log2 transformed counts were obtained 
mapping SLC16A4 (205234_at), SLC16A1 (202235_
at), HK2 (222305_at), PDHA1 (1555864_s_at), TIGAR 
(219099_at), MIR-205HG (226755_at), DLD (230426_at), 
MYC (244089_at), PPARGC1A (1569141_a_at), SNAI2 
(213139_at), ZEB1 (212764_at), VIM (201426_s_at), 
TWIST2 (229404_at), CDH1 (201131_s_at). Statistical 
analysis was performed using Prism software (GraphPad 
version 6.0 Software, La Jolla, CA, USA). Data were 
compared using Student’s t-test.
Statistical analysis
Data are presented as means ± SD from at least 
three independent experiments. Statistical analysis of the 
data was performed by Student's t test or 2-way ANOVA 
(Bonferroni corrected). P values of ≤0.05 were considered 
statistically significant.
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